Focused Pipeline

Project MOA Indication Exploratory research Preclinical Clinical study Note
Ph1 Ph2 Ph3
SCO-240

SSTR5 antagonist
  • Growth hormone deficiency
  • Infertility
  • Alopecia
   

Supported by*
SCO-483

Undisclosed (Small molecule)
  • Congenital Adrenal Hyperplasia (CAH)
  • Cushing's syndrome
     

Supported by*
Project B

Undisclosed (Peptide)
  • Lymphoedema etc.
       

Project C

Undisclosed (Small molecule)
  • Undisclosed
       

 

Value-Added Pipeline

Project MOA Indication Exploratory research Preclinical Clinical study Note
Ph1 Ph2 Ph3
SCO-272

Direct renin inhibitor
  • Diabetic kidney disease
 

  • Hypertension
   
SCO-792

Enteropeptidase inhibitor
  • Phenylketonuria (PKU)
  • Maple syrup urine disease (MSUD)
  • Homocystinuria (HCU)
   

SCO-267

GPR40 full agonist
  • Diabetes
  • Obesity
  • MASH
   

SCO-006

IP6K inhibitor
  • Hyperphosphatemia
  • Ovarian clear cell carcinoma
     

SCO-116
(except Eye/Skin)

NRF2 activator
  • Lung disease
  • MASH
  • Diabetic kidney disease
     

Eye/skin is partnered with Kuria Therapeutics

*SCOHIA is actively seeking a development and commercialization partner for Value-Added Pipeline. Contact here for partnering.

Partnered Pipeline

Project MOA Indication Exploratory research Preclinical Clinical study Partner
Ph1 Ph2 Ph3
SCO-094

GLP-1R/GIPR dual agonist
  • Diabetes
  • Obesity
   

Huadong Medicine
SCO-116
(Eye/Skin)

NRF2 activator

  • Fuchs’ Dystrophy
  • Corneal Endothelial Damage Associated With Cataract Surgery
  • Dry AMD
     

Kuria Therapeutics
Discovery
Collaboration

Undisclosed
  • Obesity
       

Undisclosed

Process of drug discovery

We are committed to building a portfolio of innovative
and sufficient R&D pipelines centered on the field of lifestyle-related diseases.

Our basic R&D strategy is to select different mechanism of action among projects at
each development stage, and to ensure that other compounds (backup compounds)
are considered in projects at the preclinical study stage,
which minimizes the development risk and
continuously enhances the drug candidate stage.

Exploratory research

Selection of drug
discovery targets

Select the target (such as protein) for the drug to work.

Screening

Screen lead compounds as potential drug seeds according to the strength of binding to the target, toxicity, and other factors.

Lead compound optimization

Select the best compound after lead compounds are repeatedly converted.

Preclinical study

Pharmacology study

Lowest effective dose?

Pharmacokinetic study

How is it absorbed, distributed, metabolized, and excreted in the body?

General pharmacology study

How does it work in the body?

General toxicity study

Does it have strong toxicity or harmful effects?

Specific toxicity study

Does it have carcinogenicity or an effect on the fetus?

Investigational New Drug Application (IND)
Clinical study

Phase 1 study

Examine the safety in a small number of healthy volunteers.

Phase 2 study

Examine the efficacy and safety in a relatively small number of patients.
(Determine the dosing regimen, etc.)

Marketing approval/launch